Teva Pharmaceuticals
TEVA
443 hedge funds and large institutions have $5.06B invested in Teva Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 52 funds opening new positions, 128 increasing their positions, 148 reducing their positions, and 58 closing their positions.
1.58% less ownership
Funds ownership: 52.94% → 51.36% (-1.6%)
3% less funds holding
Funds holding: 455 → 443 (-12)
10% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 58
14% less repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 148
26% less call options, than puts
Call options by funds: $177M | Put options by funds: $240M
29% less capital invested
Capital invested by funds: $7.14B → $5.06B (-$2.08B)
58% less funds holding in top 10
Funds holding in top 10: 12 → 5 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$99.2M |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$43.7M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$30.7M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$26.4M |
| 5 |
EP
Eversept Partners
New York
|
+$25.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$86.1M |
| 2 |
IAM
Ion Asset Management
Herzliya,
Israel
|
-$63.8M |
| 3 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$48.5M |
| 4 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
-$46.4M |
| 5 |
NC
Noked Capital
Tel Aviv,
Israel
|
-$36.5M |
TEVA Hedge Fund Activity: Q3 2020 in Review
443 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2020, worth a combined $5.06B — down 29% from $7.14B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of TEVA and 52 opened new positions — a net loss of 6 holders — while 148 trimmed existing stakes and 128 added.
The largest buyer was Capital World Investors, adding an estimated $99.2M. The largest seller was Fidelity Investments, cutting an estimated $86.1M.
- 443 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2020, down from 455 in Q2 2020.
- Funds reported $5.06B of Teva Pharmaceuticals stock for Q3 2020, down 29% quarter-over-quarter.
- 52 funds opened new Teva Pharmaceuticals positions in Q3 2020 and 58 closed out, a net change of -6 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2020 was Capital World Investors, an estimated $99.2M added.
- The largest Teva Pharmaceuticals seller in Q3 2020 was Fidelity Investments, an estimated $86.1M sold.
Based on aggregated 13F filings for Q3 2020.